Fixing genes won’t fix us
By Jim Kozubek,
Boston Globe
| 06. 01. 2017
Methadone Mile is a stretch of road along Massachusetts Avenue that begins in the South End and stretches north to the Charles River. On the other side of the river is Cambridge. For the past few years, I lived far north on this road in a $600-a-month room in a house with red paint peeling from its front clapboards. I was employed as a data scientist at the Brigham and Women’s Hospital, walking that Avenue each morning and afternoon through people in various stages of despondence, some fallen on the sidewalk, to one of my offices at the Broad Institute of MIT and Harvard.
Cambridge installed a half-million-dollar toilet near Mass. Ave in Harvard Square a year and a half ago, but that was to keep troubled people out of cafes. The big money is going toward a much different approach to longstanding social and public-health problems. Not far away, the really big, beautiful structures keep sprouting out of the ground, including Novartis’ recently completed $600 million campus, and the neighboring $1.4 billion Broad Institute with its 11 floors of...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...